Moxifloxacin

Type of Medication: Antibiotic

Indications: Second line treatment for community acquired pneumonia, used as part of regime to treat atypical mycobacterium abscessus.

Side Effects: Nausea, vomiting, dyspepsia, abdominal pain, diarrhoea (rarely antibiotic associated colitis), headache, dizziness, sleep disorders, rash (rarely Stevens-Johnson syndrome and TEN), and pruritis. Less frequent side effects include anorexia increase in urea and creatinine, drowsiness, restlessness, asthenia, depression, confusion, hallucination, convulsions, tremor, paraesthesia, hypoaesthesia, photosensitivity, hypersensitivity reactions (fever, urticaria, angioedema, arthralgia, myalgia, and anaphylaxis ), blood disorders, disturbances in vision, taste , hearing and smell. dry mouth, stomatitis, glossitis, flatulance, constipation, arrhythmias, palpitations, peripheral oedema, angina, changes in BP, dyspnoea, anxiety, hyperglycaemia and dry skin.

Route of administration: Adult (Intravenous)

Dose: 400 mg once a day

Route of administration: Adult (Oral)

Dose: 400 mg once a day

Route of administration: Paediatric (Oral)

Dose: Children: 7.5–10 mg/kg once a day.

Examples of some Drug Interactions

Interacting drug: Amiodarone – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Chlorquine and Hydroxychloroquine = Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Ciclosporin – Increased risk of nephrotoxicity

Interacting drug: Disopyramide – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Haloperidol -Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Intravenous erythromycin – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Iron – Reduces absorption of moxifloxacin

Interacting drug: Mizolastine – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: NSAID – Increased risk of convulsions

Interacting drug: Phenothiazides – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Pimozide – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Procainamide – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Quinidine – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Sertindole – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Sotolol – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Theophylline -Increases plasma concentration of theophylline, increased risk of convulsions.

Interacting drug: Tricyclic antidepressants – Increased risk of ventricular arrhythmias – avoid concomitant use

Interacting drug: Zinc – Reduces absorption of moxifloxacin